# Development of Monoclonal Antibody-mediated Interventions to Combat Malaria

> **NIH NIH N43** · ANTAGEN PHARMACEUTICALS, INC. · 2022 · $300,000

## Abstract

To support proof of concept studies for the development of a monoclonal antibody to combat malaria.

## Key facts

- **NIH application ID:** 10706432
- **Project number:** 75N93022C00020-0-9999-1
- **Recipient organization:** ANTAGEN PHARMACEUTICALS, INC.
- **Principal Investigator:** WENDA GAO
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2022-07-05 → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10706432

## Citation

> US National Institutes of Health, RePORTER application 10706432, Development of Monoclonal Antibody-mediated Interventions to Combat Malaria (75N93022C00020-0-9999-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10706432. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*